CO.DON AG

  • WKN: A1K022
  • ISIN: DE000A1K0227
  • Land: Deutschland

Nachricht vom 23.05.2019 | 13:05

CO.DON AG: Changes in the Supervisory Board

DGAP-News: CO.DON AG / Key word(s): Personnel

23.05.2019 / 13:05
The issuer is solely responsible for the content of this announcement.


CO.DON AG - Changes in the Supervisory Board

Berlin / Teltow, 23 May 2019 - Dr. Bernd Wegener, the Supervisory Board member of CO.DON AG (WKN A1K022), has notified the Executive Board of CO.DON AG that he has resigned his seat on the Supervisory Board of CO.DON AG with effect from the close of the next ordinary Annual General Meeting.

In autumn 2017 Dr Wegener resigned his position as Chairman of the Supervisory Board, which had held since 2010, for personal reasons, but remained a member of the Supervisory Board.

Dr Wegener accompanied the company on its long path to the commercialisation of a pharmaceutical innovation and his dedication made a vital contribution to its positive performance.

Professor Bauerfeind, Supervisory Board Chairman of CO.DON AG: "On behalf of the entire Supervisory Board I would like to thank Dr Wegener for his outstanding, competent work and his great commitment to the advancement of CO.DON AG."

Ralf Jakobs, CEO of CO.DON AG: "On behalf of all the employees I would like to thank Dr Wegener, who over the decisive recent years, in addition to his financial commitment as an anchor investor, always shared his extensive experience with CO.DON as an important advisor and mentor in strategic decisions. He was one of the key driving forces behind the decision to focus the product, which ultimately led to the EU marketing authorisation for the articular cartilage product developed by CO.DON AG and so to the achievement of the company's most important strategic goal to date. I too assume that even after his departure from the Supervisory Board, Dr Wegener will continue to follow the development of his long-standing investment. All the staff and the Executive Board wish him the very best for his personal and professional future."

CO.DON AG develops, produces and markets autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method is currently used in over 200 clinics in Germany and more than 14,000 patients have already been treated. In July 2017 we received marketing authorisation for the advanced therapy medicinal product Spherox from the European Medicines Agency. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs.

Further information is available from www.codon.de

Investor Relations and Press Contact:
Matthias Meißner, M.A.
Corporate communications / IR / PR
Tel. +49 (0)30 240352330
Fax +49 (0)30 240352309
Email: ir@codon.de



23.05.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Fonds Research 2019: Dt. Mittelstandsanleihen FONDS bietet attraktive Anlagemöglichkeit

Auch 2019 hat die GBC AG unter der Vielzahl an Publikumsfonds neun „Fonds Champions“ herausgefiltert. Darunter den Deutsche Mittelstandsanleihen FONDS (ISIN: LU0974225590), der eine qualitätsorientierte Strategie verfolgt und eine vielversprechende Anlagemöglichkeit in den deutschen Mittelstand bietet. Insbesondere vor dem Hintergrund des aktuellen Niedrigzinsniveaus sehen wir den Fonds als gute Chance, um attraktive Renditen zu erwirtschaften und dies verbunden mit einer traditionell niedrigen Fonds-Volatilität. Wir vergeben 5 von 5 GBC-Falken ein.

Aktuelle Research-Studie

Original-Research: dynaCERT Inc (von GBC AG): BUY dynaCERT Inc

20. September 2019